Kintor Pharmaceutical Ltd. has announced the completion of patient enrollment in the Phase III stage of a pivotal clinical trial for KX-826 tincture 1.0%, aimed at treating male adult androgenetic alopecia (AGA) in China. The trial enrolled 666 patients and is characterized by a multi-center, randomized, double-blind, vehicle-controlled design. This Phase III stage involves a 24-week treatment period, followed by a 2-week safety observation period, across 25 clinical research centers in China. The Phase II stage of the trial previously met its primary endpoints, showing statistically significant and clinically meaningful outcomes in terms of efficacy and safety. The completion of the Phase III stage is anticipated by early 2026. Results from this stage have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.